Amgen Inc (AMGN)
$273.41 -$1.14 (-0.41%) 1:43 AM 12/12/24
NASDAQ | $USD | Drug Manufacturers - GeneralStock Data
-
Market Cap
$146.52B -
Day's Range
$270.58 - $276.28 -
Volume
4,939,453 -
52 Week Low / High
$255.01 - $341.72 -
PE Ratio
34.86x -
PEG Ratio
1.96 -
Dividend Frequency
quarterly
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 10
- Strong Buy
- 4
- Buy
- 16
- Hold
- 0
- Sell
- 2
- Strong Sell
- $258.80
- Target Price
Company News
-
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound — Nov 26th, 2024
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments...
-
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? — Nov 30th, 2024
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?...
-
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? — Dec 2nd, 2024
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?...
-
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? — Dec 2nd, 2024
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?...
-
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? — Nov 29th, 2024
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? — Nov 29th, 2024
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?...
-
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound — Nov 26th, 2024
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments...
-
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound — Nov 26th, 2024
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments...
-
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? — Nov 30th, 2024
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?...
-
Dow Jones Industrial Average — Nov 26th, 2024
Dow Jones Industrial Average...
-
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? — Dec 2nd, 2024
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?...
-
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound — Nov 26th, 2024
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments...
-
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed — Nov 26th, 2024
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed. The pharma giant said its weight loss medication helped patients living with obesit...
-
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound — Nov 26th, 2024
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments...
-
Dow Jones Industrial Average — Nov 26th, 2024
Dow Jones Industrial Average...
-
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? — Dec 2nd, 2024
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?...
-
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? — Nov 29th, 2024
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?...
-
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? — Dec 2nd, 2024
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound — Nov 26th, 2024
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments...
-
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed — Nov 26th, 2024
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed. The pharma giant said its weight loss medication helped patients living with obesit...
-
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed — Nov 26th, 2024
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed. The pharma giant said its weight loss medication helped patients living with obesit...
-
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? — Nov 29th, 2024
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?...
-
Dow Jones Industrial Average — Nov 26th, 2024
Dow Jones Industrial Average...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? — Nov 29th, 2024
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?...
-
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? — Nov 29th, 2024
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?...
-
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed — Nov 26th, 2024
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed. The pharma giant said its weight loss medication helped patients living with obesit...
-
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? — Nov 30th, 2024
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?...
-
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? — Nov 30th, 2024
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Dow Jones Industrial Average — Nov 26th, 2024
Dow Jones Industrial Average...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? — Nov 30th, 2024
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? — Nov 29th, 2024
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound — Nov 26th, 2024
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? — Nov 30th, 2024
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?...
-
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? — Nov 29th, 2024
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? — Dec 2nd, 2024
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?...
-
Dow Jones Industrial Average — Nov 26th, 2024
Dow Jones Industrial Average...
-
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? — Nov 29th, 2024
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?...
-
Why Amgen's Weight Loss Result Is a Win for Eli Lilly — Nov 27th, 2024
Why Amgen's Weight Loss Result Is a Win for Eli Lilly...
-
Dow Jones Industrial Average — Nov 26th, 2024
Dow Jones Industrial Average...
-
Dow Jones Industrial Average — Nov 26th, 2024
Dow Jones Industrial Average...
Portfolio
Comprised of 1 portfolios